Year: 2023
Type: review
Study design: Systematic Review
Abstract: Background: Recently, several studies introduced the potential use of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals in radioiodine-refractory thyroid cancer (TC). Methods: The authors accomplished a comprehensive literature search of original articles concerning the performance of PSMA-targeted PET/CT in TC patients. Original papers exploring this molecular imaging examination in radioiodine-refractory TC patients undergoing restaging of their disease were included. Results: A total of 6 documents concerning the diagnostic performance of PSMA-targeted PET/CT in TC (49 patients) were included in this systematic review. The included articles reported heterogeneous values of PSMA-targeted PET/CT detection rates in TC, ranging from 25% to 100% and overall inferior to [18F]-fluorodeoxyglucose PET/CT when the two molecular imaging examinations were compared. Two studies reported the administration of [177Lu]PSMA-radioligands with theragnostic purpose in three patients. Conclusions: The available literature data in this setting are limited and heterogeneous. The employment of PET with PSMA-targeting radiopharmaceuticals in this setting did not affect patient management. Nevertheless, prospective multicentric studies are needed to properly assess its potential role in TC patients.
Source: Diagnostics
Institutions: Candiolo Cancer Institute, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University of Turin, Hospital San Pedro, Center for Biomedical Research of La Rioja, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Ente Ospedaliero Cantonale, Istituto Imaging della Svizzera Italiana, Università della Svizzera italiana, University of Lausanne
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,224
OpenAlex ID: W4319083559
